AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$LQDA

Krepp Sarah sold $19K of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 274 shares of Liquidia Corp (LQDA) at $67.76 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Sep 3, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 11:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results or regulatory news not disclosed.

Relevance 2/10Novelty 3/10Timing: post-market 2026-09-01

Background

Form 4 filing provides the first public disclosure of the insider's sale.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Chief Human Resource Officer sold 274 shares for $18,566 via a 10b5-1 plan on 2026-09-01.

Expected impact

No material move expected.

Evidence & confidence

The transaction size is trivial relative to total holdings and market cap.

Market effects

Sector

None significant for the biotech sector.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

If the insider is reducing exposure, it could signal concerns about upcoming developments.

Key entities

  • Company
    Liquidia Corp

    Biopharmaceutical company listed on NASDAQ.

  • Insider
    Krepp Sarah

    Chief Human Resource Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

AUG 31
$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

tradingview.com2 min
AUG 19
$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

fool.com3 min
AUG 13
$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

tradingview.com7 min
AUG 12
$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient

SEC EDGAR 8-K6 min